Collaboration expands access to Lunit's AI-powered pathology platform by combining it with Discovery Life Sciences' global biospecimen and specialty laboratory capabilities, enabling standardized tissue insights for biomarker research and drug development.
SEOUL, South Korea, Oct. 12, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced a strategic collaboration with Discovery Life Sciences (Discovery), a global leader in biospecimens and specialty laboratory services, to expand the adoption of the Lunit SCOPE suite, the company's AI-powered pathology platform, across biopharmaceutical research.
Discovery brings more than 25 years of assay expertise and has delivered biomarker services for more than 2,000 clinical trial programs while currently supporting over 350 active trial programs through its end-to-end specialty laboratory services across the drug development lifecycle.
Through the collaboration, Discovery and Lunit will work together with biopharma clients to apply the Lunit SCOPE suite within Discovery's biomarker and tissue analysis workflows, tailoring AI-powered pathology to each program's design. By pairing Discovery's global biospecimen network and specialty laboratory expertise with Lunit's AI-powered image analysis on client programs, the companies aim to provide pharmaceutical and biotechnology companies with standardized, quantitative tissue insights that support clinical research, translational studies, and drug development. The collaboration is expected to broaden global access to Lunit's AI-powered pathology platform for biopharmaceutical researchers and organizations.
The companies also plan to expand AI-enabled tissue analysis services that help researchers generate deeper biological insights, improve the reproducibility of tissue-based analysis, and accelerate evidence generation throughout the drug development process.
In addition, Lunit will participate in Discovery Life Sciences' Bridging Biomarker Breakthroughs to Bedsides (B4 Tour) on October 14 in South San Francisco. Yoojoo Lim, Medical Director at Lunit Oncology, will speak in an expert session and join the panel discussion, "AI in Biomarkers: What's Working, What's Next."
"AI-powered pathology only delivers on its promise when the tissue and the workflow behind it are consistent. Because we source the biospecimens and perform the tissue processing and pathology in our own laboratories, we can apply the Lunit SCOPE suite to reliably prepared samples and give our biopharma partners tissue data they can trust across their programs," said Anna Juncker-Jensen, PhD, Vice President of Scientific Affairs, Discovery Life Sciences.
"As biopharmaceutical companies increasingly seek quantitative and reproducible biomarkers to guide drug development, AI-powered pathology is becoming an essential part of modern translational research," said Brandon Suh, CEO of Lunit. "Through our collaboration with Discovery Life Sciences, we aim to bring the Lunit SCOPE suite to more biopharma researchers worldwide, enabling standardized tissue analysis that accelerates biomarker research and ultimately supports the development of next-generation therapies."
Through this collaboration, biopharma partners gain access to the Lunit SCOPE suite within Discovery's end-to-end tissue workflows, from specimen sourcing through molecular pathology and quantitative readout, all performed in Discovery's own laboratories. Integrating AI at the point of analysis gives researchers standardized, reproducible tissue data across their biomarker and translational programs.
About Lunit
Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis, empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.
Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT Breast Suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development.
Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.
About Discovery Life Sciences
Discovery Life Sciences is a global leader in biospecimens and specialty lab services, enabling the discovery and development of therapeutics and diagnostics that improve patient outcomes. Our extensive portfolio of normal and diseased human biospecimens, cellular starting materials, and preclinical ADME-tox products and services accelerates research with high-quality, highly characterized materials, complemented by expertise in cell biology. Our comprehensive suite of lab services, including molecular pathology, genomics, proteomics, and flow cytometry, delivers critical data and insights for biomarker discovery across the full spectrum of retrospective and prospective clinical trials, from assay development and validation through Phase 3 and post-approval pathologist training. With a vision to be the most trusted partner in life science research and clinical development, Discovery Life Sciences is committed to advancing scientific research and transforming lives.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Lunit and Discovery Life Sciences Collaborate to Expand AI-Powered Tissue Analysis for Biopharma Research
SAN JOSE, Calif., Oct. 12, 2026 /PRNewswire/ -- MiTAC Computing Technology Corporation, a subsidiary of MiTAC Holdings Corporation (TWSE: 3706) and a global leader in high-performance server solutions, today unveiled its latest AI infrastructure innovations at the 2026 OCP Global Summit, Booth D22, under the theme "Scaling Open AI Infra with Full-Stack Innovation."
Large-scale AI clusters and AI factories demand more than compute performance alone. MiTAC Computing takes a full-stack approach, transforming fragmented infrastructure into a cohesive, scalable foundation designed for deployment, management, and expansion.
From Scalable AI Factories to Modular Data Centers: Flexible Infrastructure for Every Scale
As AI workloads expand from training, inference, and RAG to Agentic AI, infrastructure needs vary by scale and deployment environment. MiTAC Computing's AI Infrastructure Stack spans compute, storage, and liquid-cooled servers through open platform firmware, operating systems, AI software ecosystems, and AI Pod management, providing a consistent, scalable foundation for diverse workloads.
For large-scale, centralized AI environments, MiTAC Computing delivers its Scalable AI Factory, combining full-stack capabilities with rack-scale integration to support high-density computing and continued expansion. For distributed sites or rapid buildouts, MiTAC offers modular data center solutions. The TonoForge™Modular Data Center, developed with Tonomia, incorporates MiTAC G4826Z5 liquid-cooled AI servers and rack-scale integration. Its proven 12-week deployment demonstrates how the modular approach can accelerate the deployment of high-performance GPU AI clusters.
From centralized AI factories to distributed modular data centers, MiTAC gives enterprises the flexibility to build AI infrastructure around their compute requirements, site conditions, and deployment needs.
Breaking Thermal Barriers with Advanced Liquid Cooling
Higher compute density and rack-scale AI factories are making advanced cooling critical to unlocking greater compute performance. MiTAC Computing is showcasing multiple advanced liquid cooling solutions, including a PoC with ZutaCore that integrates the MiTAC G4826Z5 with ZutaCore® HyperCool® Waterless Two-Phase Liquid Cooling technology. Using a dielectric fluid that changes phase from liquid to vapor directly at the chip, the technology removes heat generated by CPUs and GPUs at the source.
The technology demonstrates the potential to support more than 4,000W per chip and average heat flux exceeding 250W/cm². Under defined operating conditions, an annualized model indicates a pPUE as low as 1.03, highlighting the value of two-phase cooling for increasingly power-dense AI infrastructure.
On October 14, MiTAC Computing will present an Expo Hall Session exploring the evolution of high-density AI systems toward next-generation rack-scale platforms and how advanced liquid cooling can overcome thermal constraints to unlock greater compute performance.
Extending Openness Across the AI Stack
Alongside advances in hardware performance, MiTAC Computing continues to develop its Open Source Firmware Solution. The G4826Z5 demonstrates full-stack integration from bare metal to AI applications. At the platform level, MiTAC's internally developed MiOPF™ supports fast system initialization, while MiOBMC™ provides real-time hardware monitoring and telemetry, giving customers greater firmware control and customization flexibility while reducing dependence on a single vendor.
Across the software ecosystem, the G4826Z5 runs Canonical-certified Ubuntu 26.04 OS and integrates Kubernetes and the DDN Data Intelligence Platform. It also incorporates AMD ROCm™ open software stack to unlock the compute performance of AMD Instinct™ MI355X GPUs. MiTAC Computing is working with Rafay on GPU cluster management to support flexible GPU-as-a-Service (GPUaaS) resource pools, enabling on-demand compute allocation based on AI workload requirements while simplifying deployment and management.
In an Executive Session later today, MiTAC Computing will explore open infrastructure management through technologies such as Open Platform Firmware (OPF), OpenBMC, and Redfish. The discussion will examine how open standards and OCP community collaboration can improve infrastructure interoperability, and how MiCoreView™, MiTAC's infrastructure management software built on open-source technologies, can further extend management capabilities from the platform level to rack and cluster scale. MiTAC will also share practical insights into deployment, telemetry, data center rack and cluster management, and system orchestration.
New Platforms Target OCP Computing and AI Inference
MiTAC Computing is making the global debut of the C2611Z6 and showcasing the latest G4520G6E3BC-N configuration, expanding its portfolio for high-density OCP computing and enterprise AI inference.
MiTAC Computing invites OCP Global Summit attendees to visit Booth D22 and experience how full-stack innovation is helping scale open AI infrastructure.
Learn more:
About MiTAC Computing Technology Corporation
MiTAC Computing Technology Corp., a subsidiary of MiTAC Holdings, delivers comprehensive, energy-efficient server solutions backed by industry expertise dating back to the 1990s. Specializing in AI, HPC, cloud, and edge computing, MiTAC Computing employs rigorous methodologies to ensure uncompromising quality—across barebones, systems, racks, and cluster levels—fully achieving performance and integration. This commitment to quality at every level sets MiTAC Computing apart in the industry.
With a worldwide presence and end-to-end capabilities—from R&D and manufacturing to global support—MiTAC Computing provides agile, customized platforms for hyperscale data centers, HPC, and AI applications, ensuring optimal performance and scalability to meet unique business needs. By leveraging the latest advancements in AI and liquid cooling, and unifying the MiTAC brand with Intel DSG and TYAN server products, MiTAC Computing stands out for its innovative, efficient, and reliable server technology as well as its hardware and software integrated solutions—empowering businesses to meet future challenges.
MiTAC Computing Technology Corporation website: https://www.mitaccomputing.com/
AMD, the AMD logo, EPYCTM, AMD InstinctTM, and combinations thereof are trademarks of Advanced Micro Devices, Inc.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
MiTAC Computing Showcases Full-Stack Innovation to Scale Open AI Infrastructure at OCP Global Summit 2026
